Last reviewed 2026-04-20 · How we verify

Phenuride (PHENETURIDE)

Phase 2 active Small molecule

Phenuride (generic name: PHENETURIDE) is a pheneturide drug. It is currently in Phase 2 development.

Phenuride is thought to work by modulating ion channels in the nervous system.

Phenuride, also known as Pheneturide, is a small molecule drug in the pheneturide class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating ion channels in the nervous system. Phenuride is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, key safety considerations and approved indications are currently unavailable.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PHENETURIDE
Drug class	pheneturide
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your nerve cells are like electrical wires, and ion channels are like switches that control the flow of electricity. Phenuride is believed to affect these switches, helping to regulate the electrical activity in your nerves. This can help to calm down abnormal electrical activity that may be causing symptoms.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Phenuride CI brief — competitive landscape report
Phenuride updates RSS · CI watch RSS

Frequently asked questions about Phenuride

What is Phenuride?

Phenuride (PHENETURIDE) is a pheneturide drug.

How does Phenuride work?

Phenuride is thought to work by modulating ion channels in the nervous system.

What is the generic name of Phenuride?

PHENETURIDE is the generic (nonproprietary) name of Phenuride.

What drug class is Phenuride in?

Phenuride belongs to the pheneturide class. See all pheneturide drugs at /class/pheneturide.

What development phase is Phenuride in?

Phenuride is in Phase 2.

Drug class: All pheneturide drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing